evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

891 questions · 902 findings · 317 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 210 · 23.3%GRADE not reported 56 · 6.2%Very low 236 · 26.2%Low 220 · 24.4%Moderate 146 · 16.2%High 34 · 3.8%

Ozone applied to the carious lesion (10 or 40 seconds), with a fluoride reductant and oral hygiene/preventive advice vs No ozone, with a fluoride reductant and oral hygiene/preventive advice (as in the intervention group)

Adverse events · People of any age with caries (including demineralisation in non-cavitated carious lesions); the caries may affect any single tooth…
1 finding from 1 review
  • Ozone therapy for the treatment of dental caries 2004 · Cochrane All outcomes
    To 6 months
    Baysan 2003 stated that no adverse events were reported to 6 months; no information was provided by Abu-Naba'a 2003 or Abu-Naba'a 2003pilot.
    1 study
    GRADE not reported

Sunitinib vs IFN‐α (targeted agent versus classic immunotherapy)

Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

Sunitinib probably leads to higher serious adverse events (Grade 3 or 4)assessed as: CTCAE v3.0 compared with interferon‐α (IFN‐α) (targeted agent versus classic immunotherapy) (moderate certainty).

1 finding from 1 review

TDC vs medical therapy

Secondary outcome:total serious adverse events at the end of · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack

TDC showed no clear difference in secondary outcome:total serious adverse events at the end of compared with medical therapy (low certainty).

1 finding from 1 review

Summary of findings table ‐ Emicuzimab 1.5 mg/kg weekly prophylaxis vs on‐demand therapy

Serious adverse events · people without inhibitors

Summary of findings table ‐ Emicuzimab 1.5 mg/kg weekly prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Emicuzimab 3.0 mg/kg bi‐weekly prophylaxis vs on‐demand therapy

Serious adverse events · people without inhibitors

Summary of findings table ‐ Emicuzimab 3.0 mg/kg bi‐weekly prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).

1 finding from 1 review

Azathioprine vs cyclophosphamide

Serious adverse events · adults with renal vasculitis for maintenance therapy

Azathioprine showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Postoperative MMC‐EMDA with sequential BCG induction and maintenance vs postoperative BCG induction and maintenance therapy

Serious adverse events

It is very uncertain whether postoperative MMC‐EMDA with sequential BCG induction and maintenance changes serious adverse events compared with postoperative BCG induction and maintenance therapy (very low certainty).

1 finding from 1 review

Summary of Findings Table ‐ Enoxaparin vs no enoxaparin

Adverse events: clinically relevant non‐major bleeding / heparin‐induced thrombocytopenia ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review